Epizyme (Nasdaq:EPZM) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

EPZM Stock Overview

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States.

About the company

EPZM fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 37.59% per year

Risk Analysis

Highly volatile share price over the past 3 months

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

+ 1 more risk

Epizyme, Inc. Competitors

Eagle Pharmaceuticals

NasdaqGM:EGRX

US$59.1m

Sutro Biopharma

NasdaqGM:STRO

US$290.0m

Karyopharm Therapeutics

NasdaqGS:KPTI

US$131.6m

Sangamo Therapeutics

NasdaqGS:SGMO

US$105.8m

Price History & Performance

Summary of all time highs, changes and price drops for Epizyme
Historical stock prices
Current Share Price	US$1.47
52 Week High	US$5.80
52 Week Low	US$0.41
Beta	-0.42
1 Month Change	-0.68%
3 Month Change	182.37%
1 Year Change	-72.78%
3 Year Change	-89.29%
5 Year Change	-89.54%
Change since IPO	-93.61%

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12

Epizyme Q3 2020 Earnings Preview

Nov 05

Shareholder Returns

	EPZM	US Biotechs	US Market
7D	-3.3%	-2.5%	-3.2%
1Y	-72.8%	-3.7%	19.3%

Return vs Industry: EPZM underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: EPZM underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is EPZM's price volatile compared to industry and market?
EPZM volatility
EPZM Average Weekly Movement	19.9%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Stable Share Price: EPZM's share price has been volatile over the past 3 months.

Volatility Over Time: EPZM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2007	250	Grant Bogle	www.epizyme.com

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others.

Epizyme, Inc. Fundamentals Summary

How do Epizyme's earnings and revenue compare to its market cap?
EPZM fundamental statistics
Market cap	US$247.50m
Earnings (TTM)	-US$207.73m
Revenue (TTM)	US$53.01m

4.7x

P/S Ratio

-1.2x

P/E Ratio

Is EPZM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EPZM income statement (TTM)
Revenue	US$53.01m
Cost of Revenue	US$10.79m
Gross Profit	US$42.22m
Other Expenses	US$249.95m
Earnings	-US$207.73m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.23
Gross Margin	79.64%
Net Profit Margin	-391.88%
Debt/Equity Ratio	-1,148.4%

How did EPZM perform over the long term?

See historical performance and comparison

This company listing is no longer active

EPZM Stock Overview

Rewards

Risk Analysis

Epizyme, Inc. Competitors

NasdaqGM:EGRX

US$59.1m

NasdaqGM:STRO

US$290.0m

NasdaqGS:KPTI

US$131.6m

NasdaqGS:SGMO

US$105.8m

Price History & Performance

Recent News & Updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 12%

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.60

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Price target decreased to US$9.02

Price target decreased to US$9.20

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Price target increased to US$12.25

Consensus revenue estimates increase by 19%

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Epizyme: Taking Advantage Of Recent Sell-Off

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Director Kevin Conroy has joined 4th company board

Consensus revenue estimates increase to US$53.4m

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Price target decreased to US$11.14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought US$500k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Analysts lower revenue estimates to US$49.1m

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Price target lowered to US$21.25

Revenue and earnings beat expectations

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: US$10.67

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Independent Director recently bought US$60k worth of stock

Price target lowered to US$23.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Analysts update estimates

Third quarter 2020 earnings released: US$0.55 loss per share